Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 384

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 384
---
. in crop sciences and a CBA from the University of Illinois, a Master of Science degree in plant pathology and weed science from the Colorado State University and a bachelor’s degree in biochemistry from the Louisiana State University. In 2018, Federico was recognized with the Konex Award for business innovation for 2008 -18, one of Argentina’s most prestigious leadership prizes. He was also recognized with the EY Entrepreneur of the Year Award for Argentina in 2019. Mr. Trucco was appointed President of the Argentine Chamber of Biotechnology in 2020. Director Compensation The Company does not pay any additional compensation to directors who are executives or employees of the Company or to non -executive/employee directors. Heritas Argentina The name of Heritas Argentina’s directors and their ages, as of the date hereof, are as follows:

| Name            |     | Age |     | Position       |
| Fabian Fay      |     |  59 |     | President      |
| Federico Trucco |     |  47 |     | Vice President |
| Celina Trucco   |     |  57 |     | Director       |
| Laura Barberio  |     |  53 |     | Director       |

Biographical information for the members of Heritas Argentina’s board of directors is set forth below. Fabian Fay.Upon the Closing of the Business Combination, Mr. Fay is expected to serve as director of the Company. Mr. Fay has served as the Chief Executive Officer of Parent since its inception in 2021. He has held positions such as director of Grupo Oroño, an Argentinean Health Group, since 2022, member of the Endeavor Argentina Regional Board of Directors from 2015 to 2022, president of the Latin American Association of Private Clinical Laboratories since 2010 and director of Medicina Esencial, a regional health management organization since 2003. He also served as the director of ACLIRES LAB from 2007 to 2011 where he was dedicated to phase 1 clinical trials, director of Sanatorio Parque and the Sanatorio de Niños Lab from 1992 until 2004, director of the Center of Molecular Diagnostics in BioSidus from 1995 to 2001 and director and President of CIBIC Laboratories since 1990. Mr. Fay has actively overseen laboratory operations for local, regional and central laboratories for over 20 clinical trials between 1994 and 2015